Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
401 stopped studies mapped to Breast Carcinoma and descendants · 95% state a reason
Over the 401 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02095210 | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 | Phase 1 | terminated | Mar 24, 2014 | Dorte Nielsen | slow recruitment | Enrollment / accrual |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients… | Phase 1 / Phase 2 | terminated | Oct 2, 2012 | Prescient Therapeutics, Ltd. | criteria for continuing enrollment in Phase 2 portion was not met | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative… | Phase 2 | terminated | Sep 8, 2016 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | Phase 2 | withdrawn | Nov 4, 2019 | AHS Cancer Control Alberta | Sponsor withdrew support | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT01409811 | Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated… | N/A | terminated | Aug 4, 2011 | City of Hope Medical Center | Study closed after it became too difficult to interest patients in participating. | Other (stated, no rule matched) |
| NCT02774681 | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain… | Phase 2 | terminated | May 17, 2016 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01060345 | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ | Phase 2 | terminated | Feb 2, 2010 | University of Chicago | Drug no longer available | Other (stated, no rule matched) |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT03110445 | Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus(rVV-740CTA) | Phase 1 | withdrawn | Apr 12, 2017 | University Hospital, Basel, Switzerland | not sufficiently staff available to perform trial | Other (stated, no rule matched) |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT01545648 | Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in… | Phase 2 | terminated | Mar 7, 2012 | Hope Rugo, MD | Low Accrual | Enrollment / accrual |
| NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab +…(ATTILA) | Phase 3 | withdrawn | Jan 22, 2019 | iOMEDICO AG | Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP… | Other (stated, no rule matched) |
| NCT03185871 | Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses | Phase 2 | withdrawn | Jun 14, 2017 | University of Wisconsin, Madison | Slow accrual | Enrollment / accrual |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in… | Phase 2 | terminated | Jul 3, 2013 | Women's Cancer Study Group GmbH | Early termination due to significant lack of relevant patient data for evaluation of objectives. | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT03523299 | Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer | N/A | withdrawn | May 14, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Principal investigator wishes to revisit design and start a new study | Investigator |
| NCT03777579 | A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in… | Phase 3 | suspended | Dec 17, 2018 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | trial handovered to another sponser. | Other (stated, no rule matched) |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT01138553 | Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer | Early Phase 1 | terminated | Jun 7, 2010 | University of California, San Diego | Inadequate subject accrual | Enrollment / accrual |
| NCT02817607 | Study to Assess Breast Sensation Before and After Breast Cancer Treatment | N/A | withdrawn | Jun 29, 2016 | Duke University | not stated | Not stated |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Phase 1 | terminated | Mar 5, 2014 | Pfizer | The study was terminated due to a change in sponsor prioritization. | Other (stated, no rule matched) |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable… | Phase 2 | withdrawn | Aug 23, 2018 | University of Washington | No participants enrolled. | Enrollment / accrual |
| NCT02610920 | Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using… | Early Phase 1 | withdrawn | Nov 20, 2015 | Columbia University | Unable to enroll subjects | Enrollment / accrual |
| NCT02923037 | Hatha Yoga in Breast Cancer Survivors | N/A | terminated | Oct 4, 2016 | Vanderbilt-Ingram Cancer Center | Insufficient staff and funding | Funding |
| NCT00063934 | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without… | Phase 2 | terminated | Nov 24, 2014 | Pfizer | The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development.… | Safety / toxicity |
| NCT03238703 | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | Phase 4 | withdrawn | Aug 3, 2017 | Fred Hutchinson Cancer Center | Administrative closure based on sponsor recommendation, prior to subject enrollment | Enrollment / accrual |
| NCT01912963 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With… | Phase 2 | terminated | Jul 31, 2013 | Dana-Farber Cancer Institute | The study terminated early due to weak accrual. | Enrollment / accrual |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or…(VICTOR3) | Phase 2 | terminated | Nov 30, 2017 | Mario Negri Institute for Pharmacological Research | Low accrual rate | Enrollment / accrual |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT02364960 | Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)(TARGIT) | — | terminated | Feb 18, 2015 | TriHealth Inc. | Study site will join the TARGIT-US trial in lieu of this trial | Other (stated, no rule matched) |
| NCT01394211 | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | Phase 2 | terminated | Jul 14, 2011 | University of Arizona | Slow accrual | Enrollment / accrual |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT02168179 | KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed… | N/A | withdrawn | Jun 20, 2014 | Wake Forest University Health Sciences | No longer pursuing study at our site. | Other (stated, no rule matched) |
| NCT03045393 | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC(IMGN853) | Phase 1 | withdrawn | Feb 7, 2017 | Duke University | Inadequate enrollment | Enrollment / accrual |
| NCT02023008 | Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast… | N/A | terminated | Dec 30, 2013 | Wake Forest University Health Sciences | Study is not feasible | Other (stated, no rule matched) |
| NCT01776008 | Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating… | Phase 2 | terminated | Jan 25, 2013 | National Cancer Institute (NCI) | Study did not pass Stage 1 interim analysis. | Efficacy / futility |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02379585 | Fasting on Newly Diagnosed Breast Cancer(STEFNE) | Phase 1 / Phase 2 | terminated | Mar 5, 2015 | Western Regional Medical Center | PI Decision | Other (stated, no rule matched) |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | Phase 1 / Phase 2 | terminated | Feb 19, 2015 | Georgetown University | Slow accrual | Enrollment / accrual |
| NCT02708511 | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer | Phase 1 | terminated | Mar 15, 2016 | Sanjiv Sam Gambhir | not stated | Not stated |
| NCT02365662 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced… | Phase 1 | terminated | Feb 19, 2015 | AbbVie | Safety | Safety / toxicity |
| NCT02345772 | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy(Neohttp) | Phase 1 / Phase 2 | terminated | Jan 26, 2015 | Western Regional Medical Center | PI no longer at site. Data was not collected | Other (stated, no rule matched) |
| NCT01372618 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor | Phase 1 / Phase 2 | terminated | Jun 14, 2011 | NYU Langone Health | PI has passed away. Requested by department to terminate study. | Other (stated, no rule matched) |
| NCT01319539 | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | Phase 2 | terminated | Mar 21, 2011 | National Cancer Institute (NCI) | terminated early, due to toxicity | Safety / toxicity |
| NCT00899145 | Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers | — | withdrawn | May 12, 2009 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01754519 | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer… | Phase 2 | terminated | Dec 21, 2012 | Roswell Park Cancer Institute | IDE not submitted | Other (stated, no rule matched) |
| NCT01918306 | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple… | Phase 1 / Phase 2 | terminated | Aug 7, 2013 | Vanderbilt-Ingram Cancer Center | company stopped production of study drug due to excessive toxicities, lack of efficacy | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 5, 2020source: clinicaltrials